Strategic Partners A/S
86.00
EUR
0.00
(0.00%)
ISIN
DK0062502894
Return %
Stock
S&P 500
1Y
-23.89
14.20
3Y
-32.71
81.12
5Y
-97.56
68.34
Capital Structure
DKK
•
in mil. unless spec.Working Capital
DKK
•
in mil. unless spec.Growth Rates
DKK
•
in mil. unless spec.Semi-annual Revenue
DKK
•
in mil. unless spec.Semi-annual Earnings Per Share
DKK
•
in mil. unless spec.Semi-annual Dividends Per Share
DKK
•
in mil. unless spec.Company Description
- CEO
- Jakob Færch Bendtsen
- Full Time Employees
- 1
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Lyskær 8A Copenhagen CR Denmark 2730
- IPO Date
- Nov 16, 2017
- Website
- strategic-partners.dk
- Similar Companies
- Business
- Strategic Partners A/S operates as a Danish investment and strategic partnership company focused on creating value through active ownership and collaborative ventures in the life sciences and related sectors. The group engages in developing and supporting partnerships that advance early-stage to clinical-stage therapies, with an emphasis on complex genetic and rare-disease indications, including lysosomal storage disorders and protein aggregation diseases. Headquarters are in Copenhagen, Denmark, and the company maintains operations that span across Europe with a primary emphasis on Nordic and European markets. Founded in 2009, Strategic Partners A/S positions itself as an active investor in equity and strategic collaborations, pursuing minority and, where appropriate, controlling interests to drive value creation through governance, strategic alignment, and targeted development milestones. The company’s corporate structure includes direct investments in biotechnology ventures and partnerships with research institutions and pharmaceutical companies, aiming to accelerate translational potential from discovery to clinical development and beyond. Subsidiaries and portfolio entities are organized to support specialized activities in preclinical research, translational medicine, regulatory strategy, manufacturing readiness, clinical trial execution, and commercialization planning. In addition to its core investment activity, the firm seeks to leverage strategic alliances, licensing arrangements, and capital partnerships to expand its portfolio and geographic reach within the European bioscience ecosystem. Strategic Partners A/S targets partnerships with biotechnology startups, research spinouts, and mid-to-large-cap firms seeking to advance high-potential therapies through preclinical and early clinical stages, while providing strategic oversight, governance support, and value-adding resources to portfolio companies. The company’s services include deal sourcing and evaluation, structuring of strategic collaborations, minority equity investments, joint development arrangements, licensing and technology transfer support, and ongoing portfolio management designed to optimize return on investment for stakeholders. The latest major changes reflect active expansion into new therapeutic areas through partnerships and potential strategic alliances, ongoing portfolio optimization, and continued emphasis on translational science initiatives and robust governance frameworks to support accelerated development timelines. As part of its geographic and sector strategy, Strategic Partners A/S expands its footprint in Europe with formal collaborations and co-development agreements that align with evolving regulatory landscapes and funding ecosystems, enabling accelerated access to markets for innovative therapies. The company emphasizes rigorous diligence, disciplined capital deployment, and a patient-centric approach to building sustainable value for investors, partners, and patients alike.